Recent news on Mecasermin

Ipsen Wins Positive EU Panel View on Drug Increlex  -  25 May 2007
Reuters.uk,The Committee for Medicinal Products for Human Use on Friday recommended marketing clearance for Increlex, chemically known as mecasermin,

Insmed Withdraws Its Marketing Authorisation Application For IPLEX  -  27 Mar 2007
Medical News Today (press release),Mecasermin rinfabate was designated as an orphan medicinal product for the treatment of these conditions on 20 June 2006.

Insmed Withdraws Its Marketing Authorisation Application for Iplex  -  27 Mar 2007
PharmaLive.com (press release),Mecasermin rinfabate was designated as an orphan medicinal product for the treatment of these conditions on 20 June 2006.

IGF-1 Case Settled At Last; Favors Tercica Over Insmed  -  Mar 7, 2007
BioWorld Online,The FDA approved Tercica's rhIGF-1 Increlex (mecasermin) in the summer of 2005 for long-term treatment of severe primary IGFD, and Tercica launched the

Hearing Postponed in Patent Dispute by Makers of Biologics Iplex ...  -  Feb 17, 2007
Biologic Drug Report,Tercica, a California biopharmaceutical company that a year ago launched Increlex (mecasermin), is trying to get the judge to issue an injuction banning

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional